Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.…
Quantum-Si Achieves Historic Milestone in Protein Sequencing with Single-Molecule Detection of All 20 Amino Acids on Proteus™
Quantum-Si (NASDAQ: QSI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 145 employees.
The shares were at 0.9090 USD on 20 November 2026, down 42.3% over 52 weeks. Its 52-week range is 0.6900 USD to 1.810 USD: the price is 49.8% below the high and 31.7% above the low.
Its market capitalisation is 199.75M USD.
Quantum-Si reports return on equity of -46.0% and revenue down 61.6% year over year.
It holds more cash than debt, a net cash position of 100.73M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 2.267 USD is 149.4% above the current price. The next earnings report is expected on 3 March 2027.